Home›Research›Compare›Oxyntomodulin vs Tirzepatide
Peptide ComparisonOxyntomodulin vs Tirzepatide
Both are Metabolic peptides.
Oxyntomodulin
OXM
No providers listed yet
Tirzepatide
Mounjaro
Half-life: ~5 days (once-weekly dosing)
536 providers listed
Tirzepatide is FDA-approved, while Oxyntomodulin is investigational — the clearest structural difference between them.
Oxyntomodulin
Evidence
Half-life
—
Tirzepatide
Evidence
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Further along in FDA review | Tirzepatide |
| More provider options (0 vs 536) | Tirzepatide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Oxyntomodulin
Tirzepatide
Oxyntomodulin
Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…
Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…
Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…
Oxyntomodulin reduces energy intake and adiposity in overweight and obese subjects
+7 more
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agoni…
+9 more
About Oxyntomodulin
Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Oxyntomodulin
Class-based (investigational)
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Oxyntomodulin
Not enough vendor pricing yet.
Tirzepatide
Where to source these peptides
Oxyntomodulin
Browse directory →
Providers offeringTirzepatide
536 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Oxyntomodulin vs Tirzepatide — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/oxyntomodulin/tirzepatide